| P2093 | author name string | John H Krystal | |
| | Graeme F Mason | |
| P2860 | cites work | Accumulation of fluoxetine and norfluoxetine in human brain during therapeutic administration | Q48414122 |
| | NMR determination of the TCA cycle rate and alpha-ketoglutarate/glutamate exchange rate in rat brain | Q48489904 |
| | Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy | Q48614993 |
| | Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics. A pilot study of the dorsal prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance spectroscopy | Q48712833 |
| | Lower levels of nucleoside triphosphate in the basal ganglia of depressed subjects: a phosphorous-31 magnetic resonance spectroscopy study | Q48823084 |
| | Favorable effect on neuronal viability in the anterior cingulate gyrus due to long-term treatment with atypical antipsychotics: an MRSI study. | Q51960889 |
| | Simultaneous determination of the rates of the TCA cycle, glucose utilization, alpha-ketoglutarate/glutamate exchange, and glutamine synthesis in human brain by NMR. | Q52359051 |
| | Synthesis of N-acetyl-l-aspartate by rat brain mitochondria and its involvement in mitochondrial/cytosolic carbon transport | Q28252492 |
| | Brain proton magnetic resonance spectroscopy (1H-MRS) in Alzheimer's disease: changes after treatment with xanomeline, an M1 selective cholinergic agonist | Q42547240 |
| | Preliminary evidence of low cortical GABA levels in localized 1H-MR spectra of alcohol-dependent and hepatic encephalopathy patients | Q48192251 |
| | Human brain fluoxetine concentrations | Q48371795 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 690-701 | |
| P577 | publication date | 2006-10-01 | |
| P1433 | published in | NMR in Biomedicine | Q3061252 |
| P1476 | title | MR spectroscopy: its potential role for drug development for the treatment of psychiatric diseases | |
| P478 | volume | 19 | |